We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-2.69%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$195M
AUM Growth
-$51.6M
Cap. Flow
-$43.8M
Cap. Flow %
-22.51%
Top 10 Hldgs %
61.32%
Holding
72
New
17
Increased
14
Reduced
19
Closed
22

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.8M
2
BDX icon
Becton Dickinson
BDX
+$17.1M
3
SBRA icon
Sabra Healthcare REIT
SBRA
+$9.02M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$7.54M
5
QGEN icon
Qiagen
QGEN
+$6.63M

Top Sells

Rank Stock Value
1
LH icon
Labcorp
LH
+$10.9M
2
CNC icon
Centene
CNC
+$9.85M
3
MRK icon
Merck
MRK
+$8.25M
4
ICLR icon
Icon
ICLR
+$7.14M
5
CI icon
Cigna
CI
+$6.37M

Sector Composition

Rank Sector Weight
1 Healthcare 91.97%
2 Real Estate 8.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
51
Alnylam Pharmaceuticals
ALNY
$29.3B
– –
-4,596
Closed -$1.09M
ARWR icon
52
Arrowhead Research
ARWR
$12.4B
– –
-28,187
Closed -$1.14M
ATNM icon
53
Actinium Pharmaceuticals
ATNM
$25M
– –
-45,612
Closed -$486K
AXSM icon
54
Axsome Therapeutics
AXSM
$10.9B
– –
-11,264
Closed -$869K
BCAB icon
55
BioAtla
BCAB
$5.74M
– –
-2,728
Closed -$1.13M
BMEA icon
56
Biomea Fusion
BMEA
$91.3M
– –
-33,881
Closed -$286K
BNTX icon
57
BioNTech
BNTX
$23.5B
– –
-21,664
Closed -$3.25M
CRL icon
58
Charles River Laboratories
CRL
$12.8B
– –
-6,258
Closed -$1.36M
ELUT icon
59
Elutia
ELUT
$37.6M
– –
-1,259,544
Closed -$5.35M
HCA icon
60
HCA Healthcare
HCA
$89.5B
– –
-6,595
Closed -$1.58M
IGMS
61
DELISTED
IGM Biosciences
IGMS
– –
-30,320
Closed -$516K
ITOS
62
DELISTED
iTeos Therapeutics
ITOS
– –
-21,041
Closed -$411K
NTLA icon
63
Intellia Therapeutics
NTLA
$1.67B
– –
-16,401
Closed -$572K
STRO icon
64
Sutro Biopharma
STRO
$421M
– –
-28,190
Closed -$2.28M
TERN
65
DELISTED
Terns Pharmaceuticals
TERN
– –
-135,994
Closed -$1.38M
TXG icon
66
10x Genomics
TXG
$6.61B
– –
-30,357
Closed -$1.11M
SILK
67
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-29,967
Closed -$1.58M
ALBO
68
DELISTED
Albireo Pharma Inc
ALBO
– –
-217,209
Closed -$4.69M
OYST
69
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
– –
-19,927
Closed -$223K
INBX
70
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-13,485
Closed -$332K
1 2
3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Endurant Capital Management held 72 positions worth $195M, down 21% from $246M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Endurant Capital Management withdrew a net $43.8M in Q1 2023, closing 22 positions and reducing 19 holdings. Its most notable exit was Elutia, an estimated $5.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 74% a quarter earlier, followed by Real Estate.

Against the trend, Endurant Capital Management opened a new position in Teva Pharmaceuticals worth $6.75M.

  • Endurant Capital Management's largest Q1 2023 buy was Teva Pharmaceuticals: 762,264 shares worth $6.75M.
  • Endurant Capital Management added most to BioMarin Pharmaceuticals in Q1 2023, an estimated $17.8M increase.
  • Endurant Capital Management's biggest Q1 2023 reduction was Labcorp, cutting an estimated $10.9M.
  • Endurant Capital Management fully exited Elutia in Q1 2023, selling an estimated $5.35M.
  • Endurant Capital Management's ten largest holdings make up 61% of its $195M portfolio in Q1 2023.
  • Endurant Capital Management opened 17 new positions and closed 22 in Q1 2023.
  • Endurant Capital Management's portfolio value fell 21% quarter-over-quarter to $195M.

Based on Endurant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.